KPRX KIORA PHARMACEUTICALS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1372514 · Fiscal year ends 12/31
Financial factors as of 2025-03-31 (2025Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-99.9%
TTM net income YoY-529.2%
TTM EPS YoY84.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-55,210.8%
Net margin-60,257.3%
FCF margin—
EBITDA margin-55,137.5%
Returns
ROE-41.1%
ROA-31.5%
ROIC (approx.)-74.1%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets30.3%
Debt / equity0.00x
Current ratio5.14x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.64x
Accruals ratio-11.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.00M | — | — | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $1.95M | $2.08M | $2.12M | $2.93M | $2.73M | $2.59M | $2.53M | $4.12M |
| SG&A expense | $1.58M | $1.38M | $1.61M | $1.46M | $1.44M | $1.35M | $1.49M | $1.33M |
| Operating income | -$1.69M | -$2.21M | -$2.51M | -$7.31M | -$794,437 | -$2.40M | -$2.33M | -$2.56M |
| Pretax income | -$1.58M | -$2.08M | -$2.42M | -$7.17M | -$616,323 | -$2.26M | -$2.07M | -$2.16M |
| Income tax | $165,000 | $0 | $0 | -$649,970 | -$643,129 | -$112,057 | $123,006 | $2.07M |
| Net income | -$1.75M | -$2.08M | -$2.42M | -$6.52M | $26,806 | -$2.15M | -$2.19M | -$4.22M |
| EBITDA | -$1.68M | -$2.20M | -$2.50M | -$7.30M | -$783,885 | -$2.39M | -$2.33M | -$2.56M |
| EPS (basic) | -0.28 | -0.34 | -0.58 | — | 0.01 | -0.54 | -0.52 | — |
| EPS (diluted) | -0.28 | -0.34 | -0.58 | — | 0.01 | -0.54 | -0.52 | — |
| Weighted avg. shares (diluted) | 6.30M | 6.18M | 4.17M | — | 4.36M | 3.99M | 4.22M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $5.57M | $7.08M | $10.96M | $8.70M | $5.51M | $1.03M | $3.78M | $3.80M |
| Short-term investments | $10.72M | $9.76M | $2.92M | $8.39M | $13.87M | $19.64M | $20.33M | $23.00M |
| Receivables | $636,756 | $1.09M | $1.54M | $1.52M | $1.21M | $2.42M | $1.34M | $601,197 |
| Current assets | $19.91M | $21.26M | $18.68M | $21.75M | $22.69M | $24.74M | $27.11M | $29.71M |
| PP&E, net | $88,192 | $99,637 | $86,815 | $91,672 | $101,807 | $106,843 | $4,984 | $5,232 |
| Intangibles | $2.06M | $2.06M | $2.06M | $2.06M | $6.69M | $6.69M | $6.69M | $6.69M |
| Total assets | $22.37M | $23.78M | $21.23M | $24.25M | $29.86M | $31.95M | $34.02M | $36.48M |
| Current liabilities | $2.52M | $2.37M | $2.80M | $3.63M | $2.58M | $3.19M | $5.27M | $6.01M |
| Total liabilities | $7.08M | $6.92M | $7.29M | $8.13M | $7.45M | $9.82M | $10.32M | $10.72M |
| Shareholders' equity | $15.30M | $16.86M | $13.93M | $16.13M | $22.41M | $22.13M | $23.70M | $25.76M |
| Shares outstanding | 4.42M | 4.43M | 3.99M | 3.76M | 3.43M | 3.43M | 3.00M | 3.00M |
| Cash flow statement | ||||||||
| Operating cash flow | -$557,518 | -$1.89M | -$3.16M | -$2.18M | -$1.27M | -$3.80M | -$2.70M | -$2.25M |
| Capital expenditure | $355 | $23,456 | $5,018 | $78,163 | $431 | $32,195 | $0 | -$45,031 |
| Free cash flow | -$557,873 | -$1.92M | -$3.17M | -$2.26M | -$1.27M | -$3.84M | -$2.70M | -$2.21M |
| Investing cash flow | -$958,330 | -$6.89M | $5.40M | $5.35M | $5.74M | $664,172 | $2.67M | $482,683 |
| Financing cash flow | -$7,397 | $4.92M | -$842 | $296 | $0 | $265,359 | $0 | $0 |
| Depreciation & amortization | $12,141 | $10,741 | $10,563 | $10,508 | $10,552 | $3,423 | $318 | $5,912 |
| Stock-based compensation | $186,196 | $109,310 | $209,510 | $234,448 | $254,398 | $262,774 | $148,616 | $160,180 |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.